Skip to content
Buy This GLP
← Research
Evidence

Does Semaglutide Help Peripheral Artery Disease?

In STRIDE, semaglutide improved treadmill walking distance in adults with symptomatic PAD and type 2 diabetes.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Change in maximum walking distance, 52 weekssemaglutide×1.21placebo×1.08Estimated treatment ratio versus placebo: 1.13.792 patients, all with peripheral artery disease and type 2 diabetes.

Leg pain during walking from poor circulation is a different problem from the loss of sensation that can accompany diabetic peripheral neuropathy. STRIDE studied people with both type 2 diabetes and symptomatic peripheral artery disease (PAD). It measured how far participants could walk on a treadmill [1].

What did STRIDE find?

Researchers randomized 396 participants to weekly 1 mg semaglutide injections and 396 to placebo. At 52 weeks, the estimated median maximum distance on a fixed-workload treadmill was 1.21 times baseline in the semaglutide group and 1.08 times baseline in the placebo group. The estimated treatment ratio was 1.13 (95% CI 1.06 to 1.21). The 13% difference describes the comparison of changes from baseline in the two groups. An individual’s improvement can vary [1].

The trial recorded six serious events in five semaglutide participants and nine in six placebo participants that were considered possibly or probably related to treatment. No deaths were attributed to treatment. All participants had type 2 diabetes [1].

How does this fit into PAD care?

ACC and AHA guidance for people with PAD and type 2 diabetes discusses semaglutide and liraglutide to reduce the risk of major cardiovascular events [2][3]. STRIDE addressed a separate question about walking ability in this population. The U.S. Ozempic injection label includes cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. It does not list improved walking as a separate approved use [4].

Structured exercise, smoking cessation when relevant and management of cardiovascular risk factors remain part of PAD care [2]. A clinician can help you distinguish leg symptoms caused by poor blood flow from other causes and discuss treatment based on your diagnosis.

Frequently asked

Does semaglutide help people with peripheral artery disease walk farther?
In a randomized trial of adults with symptomatic peripheral artery disease and type 2 diabetes, the estimated treatment ratio for maximum treadmill walking distance relative to baseline was 1.13 versus placebo at 52 weeks.
Does that result apply if I do not have diabetes?
The trial only enrolled people with type 2 diabetes. It does not show what benefit people without diabetes might see.

Sources

  1. [1] Bonaca MP, et al. (2025). Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial The Lancet. PMID 40169145
  2. [2] Gornik HL, et al. (2024). Guideline for the Management of Lower Extremity Peripheral Artery Disease American College of Cardiology and American Heart Association. Source
  3. [3] American College of Cardiology and American Heart Association Joint Committee on Performance Measures (2026). 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease Circulation: Cardiovascular Quality and Outcomes. Source
  4. [4] Novo Nordisk (2026). Ozempic U.S. prescribing information Food and Drug Administration. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence